Allergan Agrees to $2.74 Million Payments in Generics Case

Drug Industry Daily
A A
Allergan has agreed to pay $2.74 million to three labor union health funds in a bid to bring antitrust litigation against the drugmaker to a close. The payments, revealed in documents filed in the U.S. District Court for Massachusetts, resolves claims from certain plaintiffs that alleged anticompetitive behavior related to the ulcerative colitis drug Asacol (mesalamine).

To View This Article:

Login

Subscribe To Drug Industry Daily